Delcath Announces Agreement With the Frankfurt University Hospital for Launch of Hepatic CHEMOSAT Delivery System in Germany
Delcath Systems, Inc. (NASDAQ: DCTH) announced today that the Company has entered into an initial launch and training agreement for the Delcath Hepatic CHEMOSAT® Delivery system with Johann Wolfgang Goethe University Hospital (J.W. Goethe), a premier European cancer treatment and research center located in Frankfurt, Germany. Under the terms of the agreement, the Company will provide J.W. Goethe with logistics and clinical training support in the performance of chemosaturation therapy using the CHEMOSAT system. The Company expects to conduct the training using the Generation Two version of the CHEMOSAT system, pending CE Mark approval, and for training to begin at the J.W. Goethe University Hospital in February 2012.
University Professor Dr. Thomas J. Vogl, Director of the Institute for Diagnostic and Interventional Radiology at J.W. Goethe, said, "Our team is excited to bring use of the CHEMOSAT system to Germany. Clinical research suggests that chemosaturation therapy using the CHEMOSAT system will offer us a clinically significant tool in treating liver metastases with melphalan. We're eager to begin providing therapy to our patients and exploring the additional potential benefits that the newest generation product from Delcath provides."
"This agreement marks another key milestone in the execution of our commercialization strategy for the CHEMOSAT system in the European Union," said Eamonn P. Hobbs, President and CEO of Delcath Systems. "Germany is the largest market in the EU and we are excited to be entering it with a partner as prestigious as J.W. Goethe. CHEMOSAT will be available to patients in Germany soon, and this latest agreement further positions us to begin realizing the system's potential throughout Europe in 2012."
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.